AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33941281 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-9 blockade
Number of subjects: 0
Study 33941281 — intervention group
Group type: COMPARATOR
Intervention: Serum IL-9-producing CD4(+) T cell percentages, IL-9, and D-lactate levels
Number of subjects: 0
Study 33941784 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib (PARP inhibitor)
Number of subjects: 0
Study 33941878 — intervention group
Group type: EXPERIMENTAL
Intervention: WNT974 (10 mg once-daily)
Number of subjects: 94
Study 33942031 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 serology testing
Number of subjects: 3028
Study 33942031 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic COVID-19
Number of subjects: 3028
Study 33942031 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentrations of C-reactive protein
Number of subjects: 3028
Study 33942031 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher numbers of recent disease flares
Number of subjects: 3028
Study 33942031 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of biological therapy
Number of subjects: 3028
Study 33942031 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent disease flares
Number of subjects: 3028
Study 33942031 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment changes due to the pandemic
Number of subjects: 3028
Study 33942128 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib treatment
Number of subjects: 50
Study 33942298 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel MYC-non-IG fusion treatment
Number of subjects: 0
Study 33942348 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab-bendamustine for a median of 6 cycles
Number of subjects: 175
Study 33942358 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision rule informed by multivariate analysis
Number of subjects: 1288
Study 33942358 — intervention group
Group type: EXPERIMENTAL
Intervention: BI-RADS descriptors associated with malignancy
Number of subjects: 1288
Study 33942358 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathologic evaluation
Number of subjects: 1288
Study 33942358 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-reader reliability of BI-RADS descriptors
Number of subjects: 1288
Study 33942491 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab induction followed by belatacept/rapamycin-based immunosuppression over 36 months
Number of subjects: 0
Study 33942491 — intervention group
Group type: COMPARATOR
Intervention: Alemtuzumab induction followed by belatacept/rapamycin-based immunosuppression
Number of subjects: 0
Study 33942621 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized diluted diesel exhaust (300 µg/m³)
Number of subjects: 16
Study 33942621 — intervention group
Group type: COMPARATOR
Intervention: Filtered air with an exposure mask
Number of subjects: 16
Study 33942621 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 16
Study 33942675 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 120
Study 33942745 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricothyroid method for lignocaine administration
Number of subjects: 365
Study 33942745 — intervention group
Group type: COMPARATOR
Intervention: Spray-as-you-go method for lignocaine administration
Number of subjects: 365
Study 33942954 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab plus radiation therapy, cyclophosphamide, and granulocyte macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 15
Study 33943025 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM group (93 individuals with obesity and T2DM)
Number of subjects: 174
Study 33943025 — intervention group
Group type: COMPARATOR
Intervention: OB group (66 individuals with obesity without T2DM)
Number of subjects: 174
Study 33943025 — intervention group
Group type: COMPARATOR
Intervention: NGT group (15 individuals with normal BMI and normal glucose tolerance)
Number of subjects: 174
Study 33943025 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipocyte hypertrophy
Number of subjects: 174
Study 33944790 — intervention group
Group type: EXPERIMENTAL
Intervention: SensiumVitals monitoring system (preimplementation phase) alongside usual care
Number of subjects: 0
Study 33944790 — intervention group
Group type: EXPERIMENTAL
Intervention: SensiumVitals monitoring system with digital alerts (postimplementation phase)
Number of subjects: 0
Study 33944807 — intervention group
Group type: EXPERIMENTAL
Intervention: External obturator footprint as a landmark for stem depth
Number of subjects: 135
Study 33944810 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Physical Therapy after Multiligament Surgery
Number of subjects: 0
Study 33944810 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 33944977 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial microwave scanner in conjunction with nine brain biomarkers (Aβ40, Aβ42, GFAP, H-FABP, S100B, NF-L, NSE, UCH-L1 and IL-10)
Number of subjects: 0
Study 33944977 — intervention group
Group type: COMPARATOR
Intervention: Head CT scan
Number of subjects: 0
Study 33945045 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial sonography (TCS)
Number of subjects: 100
Study 33945049 — intervention group
Group type: EXPERIMENTAL
Intervention: RC48 (2.5 mg/kg Q2W)
Number of subjects: 57
Study 33945049 — intervention group
Group type: EXPERIMENTAL
Intervention: RC48
Number of subjects: 57
Study 33945291 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with or without focal proton or photon radiation therapy (RT)
Number of subjects: 139
Study 33945296 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab plus high-dose trastuzumab (6 mg/kg weekly)
Number of subjects: 39
Study 33945297 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib 24 mg once daily until disease progression or treatment intolerance
Number of subjects: 111
Study 33945304 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time Continuous Glucose Monitoring (RT-CGM)
Number of subjects: 0
Study 33945304 — intervention group
Group type: COMPARATOR
Intervention: Capillary glucose monitoring
Number of subjects: 0
Study 33945497 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable sensors (Fitbit Charge 3 smartwatch and TempTraq temperature patches) and smartphone-based symptom logging for 30 days.
Number of subjects: 226
Study 33945497 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily mood score logging and symptom reporting via smartphone app (Roadmap 2.0) for 30 days.
Number of subjects: 226
Study 33945497 — intervention group
Group type: EXPERIMENTAL
Intervention: Biospecimen collection (nasal swabs, saliva swabs, and blood) for up to 1 year.
Number of subjects: 226
Study 33945596 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS) with 2.4 ml SonoVue intravenous bolus
Number of subjects: 2062
Study 33945596 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS)
Number of subjects: 2062
Study 33945605 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-blood standard flow cytometric assay to identify pathogenic antibodies associated with VITT
Number of subjects: 0
Study 33945627 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan-based hydrogel supplemented with gelatine and Link N (LN)
Number of subjects: 0
Study 33945627 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan-based hydrogel with gelatine
Number of subjects: 0
Study 33945627 — intervention group
Group type: COMPARATOR
Intervention: Transforming growth factor (TGF)-β (positive control)
Number of subjects: 0
Study 33946038 — intervention group
Group type: COMPARATOR
Intervention: Critically ill ICU patients
Number of subjects: 51
Study 33946038 — intervention group
Group type: COMPARATOR
Intervention: WBP of most AA
Number of subjects: 51
Study 33946038 — intervention group
Group type: COMPARATOR
Intervention: Critically ill ICU patients (SOFA 8-16)
Number of subjects: 51
Study 33946038 — intervention group
Group type: COMPARATOR
Intervention: WBP of glutamate and glutamine
Number of subjects: 51
Study 33947116 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-appealing packaging (CAP) coding tool
Number of subjects: 15
Study 33947116 — intervention group
Group type: EXPERIMENTAL
Intervention: Mock breakfast cereal packages
Number of subjects: 15
Study 33947168 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-mismatching (A-B-C-DR-DQ)
Number of subjects: 105
Study 33947205 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral Artery Questionnaire (PAQ) summary scale improvement
Number of subjects: 483
Study 33947205 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral Artery Questionnaire (PAQ) summary scale worsening
Number of subjects: 483
Study 33947209 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 1765
Study 33947209 — intervention group
Group type: COMPARATOR
Intervention: Control (no alteplase)
Number of subjects: 1765
Study 33947209 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 1765
Study 33947359 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping via saliva samples and bloodspots; comprehensive online phenotyping.
Number of subjects: 14500
Study 33947359 — intervention group
Group type: COMPARATOR
Intervention: Controls (1500 individuals)
Number of subjects: 14500
Study 33947421 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid meal with moderate protein and carbohydrate content
Number of subjects: 10
Study 33947421 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized liquid meal
Number of subjects: 10
Study 33947421 — intervention group
Group type: EXPERIMENTAL
Intervention: Two different meals
Number of subjects: 10
Study 33947443 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid soap
Number of subjects: 0
Study 33947443 — intervention group
Group type: EXPERIMENTAL
Intervention: Scented soap bar
Number of subjects: 0
Study 33947443 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror
Number of subjects: 0
Study 33947443 — intervention group
Group type: COMPARATOR
Intervention: Control arm (standard hygiene kit)
Number of subjects: 0
Study 33947471 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR-only
Number of subjects: 40
Study 33947471 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR combined with Dialectical Behaviour Therapy
Number of subjects: 40
Study 33947471 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginary Rescripting (ImRs)
Number of subjects: 40
Study 33947471 — intervention group
Group type: EXPERIMENTAL
Intervention: ImRs combined with Schema Focused Therapy
Number of subjects: 40
Study 33947471 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study 33947696 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib + fixed-dose vemurafenib
Number of subjects: 18
Study 33947696 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcriptomic data
Number of subjects: 18
Study 33947698 — intervention group
Group type: EXPERIMENTAL
Intervention: KA2507
Number of subjects: 0
Study 33947745 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediator of DNA Damage Checkpoint 1 (MDC1) as an estrogen receptor coregulator
Number of subjects: 0
Study 33947785 — intervention group
Group type: EXPERIMENTAL
Intervention: Large mitochondrial DNA (mtDNA) deletions in skin biopsies
Number of subjects: 67
Study 33948050 — intervention group
Group type: EXPERIMENTAL
Intervention: Filiation service (serve/FP)
Number of subjects: 442
Study 33948050 — intervention group
Group type: COMPARATOR
Intervention: Filiation service (did not serve/FN)
Number of subjects: 442
Study 33948050 — intervention group
Group type: EXPERIMENTAL
Intervention: FP group
Number of subjects: 442
Study 33948123 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront brain radiotherapy (BR) with chemotherapy (platin-pemetrexed and bevacizumab), followed by maintenance pemetrexed with or without bevacizumab.
Number of subjects: 91
Study 33948123 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (ChT) with brain radiotherapy (BR) only at cerebral progression.
Number of subjects: 91
Study 33948191 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement intervention
Number of subjects: 10000
Study 33948191 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10000
Study 33948447 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLR treatment
Number of subjects: 216
Study 33948447 — intervention group
Group type: COMPARATOR
Intervention: Non-ACLR treatment
Number of subjects: 216
Study 33948606 — intervention group
Group type: EXPERIMENTAL
Intervention: DSM-XC (two-factor solution by Lace & Merz, 2020)
Number of subjects: 3533
Study 33948606 — intervention group
Group type: EXPERIMENTAL
Intervention: DSM-XC (six-factor solution)
Number of subjects: 3533
Study 33948606 — intervention group
Group type: EXPERIMENTAL
Intervention: DSM-XC (bifactor solution)
Number of subjects: 3533
Study 33948803 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician financial incentive payment of $75 for producing a written post-discharge care plan.
Number of subjects: 409289
Study 33949004 — intervention group
Group type: EXPERIMENTAL
Intervention: Screw-retained one-piece implant crowns fabricated with zirconia abutments
Number of subjects: 32
Study 33949080 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant removal due to peri-implantitis with simultaneous bone regeneration procedures and the use of a removal kit
Number of subjects: 26
Study 33949080 — intervention group
Group type: COMPARATOR
Intervention: Implant removal due to peri-implantitis
Number of subjects: 26
Study 33949343 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecobionics device
Number of subjects: 44
Study 33949944 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced ventilatory response to exercise (VE/VCO2 ratio)
Number of subjects: 70
Study 33949944 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak oxygen consumption
Number of subjects: 70
Study 33949954 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor feedback duration in the first quarter
Number of subjects: 10
Study 33949954 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor feedback duration in the second quarter
Number of subjects: 10
Study 33949954 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor feedback duration in the third quarter
Number of subjects: 10
Study 33949954 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor feedback duration in the fourth quarter
Number of subjects: 10
Study 33949954 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall feedback duration across 12 months
Number of subjects: 10
Study 33949959 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Internet-delivered cognitive behavioral therapy (ICBT)
Number of subjects: 83
Study 33949966 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 Decompensation Index (CDI)
Number of subjects: 0
Study 33949966 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning techniques on a large data set of patients with COVID-19
Number of subjects: 0
Study 33949966 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of the pinpointIQ digital platform
Number of subjects: 0
Study 33950216 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical sleeve gastrectomy (VSG)
Number of subjects: 36
Study 33950216 — intervention group
Group type: COMPARATOR
Intervention: Preoperative connectivity of PUT.R
Number of subjects: 36
Study 33950298 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 kDa translocator protein (TSPO) tracers
Number of subjects: 0
Study 33950298 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical samples
Number of subjects: 0
Study 33951076 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based active surveillance
Number of subjects: 350
Study 33951076 — intervention group
Group type: EXPERIMENTAL
Intervention: Serostatus determination at enrolment
Number of subjects: 350
Study 33951076 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for suspected dengue cases (RT-qPCR, NS1 assay, IgG and IgM assays)
Number of subjects: 350
Study 33951232 — intervention group
Group type: COMPARATOR
Intervention: Preataxic mutation carriers
Number of subjects: 321
Study 33951232 — intervention group
Group type: COMPARATOR
Intervention: Ataxic mutation carriers
Number of subjects: 321
Study 33951232 — intervention group
Group type: EXPERIMENTAL
Intervention: Pontine volume
Number of subjects: 321
Study 33951232 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate model
Number of subjects: 321
Study 33951488 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic TruClear tissue removal system (Medtronic, Minneapolis, MN)
Number of subjects: 10
Study 33951732 — intervention group
Group type: EXPERIMENTAL
Intervention: CEBPA-bZip mutations (including CEBPA-double-mutated)
Number of subjects: 2958
Study 33951732 — intervention group
Group type: COMPARATOR
Intervention: CEBPA-wild-type (CEBPA-WT)
Number of subjects: 2958
Study 33951732 — intervention group
Group type: EXPERIMENTAL
Intervention: CEBPA mutations with co-occurring CSF3R mutations
Number of subjects: 2958
Study 33951732 — intervention group
Group type: EXPERIMENTAL
Intervention: CEBPA-mutant or CSF3R-WT
Number of subjects: 2958
Study 33951890 — intervention group
Group type: EXPERIMENTAL
Intervention: vorinostat/Gem/BuMel
Number of subjects: 501
Study 33951890 — intervention group
Group type: EXPERIMENTAL
Intervention: Gem/BuMel
Number of subjects: 501
Study 33951890 — intervention group
Group type: EXPERIMENTAL
Intervention: BEAM
Number of subjects: 501
Study 33951890 — intervention group
Group type: EXPERIMENTAL
Intervention: BuMel
Number of subjects: 501
Study 33951890 — intervention group
Group type: COMPARATOR
Intervention: BEAM (2005-2007)
Number of subjects: 501
Study 33951890 — intervention group
Group type: COMPARATOR
Intervention: BEAM (2008-2011)
Number of subjects: 501
Study 33951890 — intervention group
Group type: COMPARATOR
Intervention: BEAM (2012-2015)
Number of subjects: 501
Study 33951890 — intervention group
Group type: COMPARATOR
Intervention: BEAM (2016-2019)
Number of subjects: 501
Study 33951923 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional MVD (FFR-significant, functional multivessel disease)
Number of subjects: 610
Study 33951923 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional SVD (FFR nonsignificant multivessel disease)
Number of subjects: 610
Study 33951923 — intervention group
Group type: EXPERIMENTAL
Intervention: SVD (angiographic single vessel disease)
Number of subjects: 610
Study 33952255 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly identified scleroedema patients with type 2 diabetes
Number of subjects: 113
Study 33952255 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated cohort of patients with scleroedema and diabetes
Number of subjects: 113
Study 33952255 — intervention group
Group type: COMPARATOR
Intervention: Patients without scleroedema
Number of subjects: 113
Study 33952263 — intervention group
Group type: EXPERIMENTAL
Intervention: Replicating Effective Programs (REP) guided implementation including facilitation, technical assistance, and implementation tools to deliver the training program.
Number of subjects: 0
Study 33952335 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli isolates from bloodstream infections
Number of subjects: 912
Study 33952335 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylogroup distribution and virulence gene content
Number of subjects: 912
Study 33952335 — intervention group
Group type: EXPERIMENTAL
Intervention: STc analysis
Number of subjects: 912
Study 33952335 — intervention group
Group type: EXPERIMENTAL
Intervention: Within STc131, 95 and 69 genomic diversity analysis
Number of subjects: 912
Study 33952335 — intervention group
Group type: EXPERIMENTAL
Intervention: STc10
Number of subjects: 912
Study 33952345 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week compressed course of left dorsolateral prefrontal (L DLPFC) 5 Hz accelerated rTMS (aTMS)
Number of subjects: 60
Study 33952345 — intervention group
Group type: COMPARATOR
Intervention: 4-week course of non-accelerated rTMS
Number of subjects: 60
Study 33952345 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Hz L DLPFC aTMS treatments for non-responders
Number of subjects: 60
Study 33952348 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextual Body Image Questionnaire for Athletes (CBIQA)
Number of subjects: 0
Study 33952425 — intervention group
Group type: EXPERIMENTAL
Intervention: AF-ESUS score
Number of subjects: 0
Study 33952541 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD group (n=80) with current diagnosis of PTSD
Number of subjects: 160
Study 33952541 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=80) with history of trauma but no current or past psychiatric diagnoses
Number of subjects: 160
Study 33952541 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD symptom dimensions (fear and dysphoria) measured with fear conditioning paradigm and attention allocation task
Number of subjects: 160
Study 33952541 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of autonomic imbalance, inflammation, and oxidative stress as potential pathway variables
Number of subjects: 160
Study 33952559 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose ibuprofen (10 mg/kg followed by two doses of 5 mg/kg at 24 hours intervals)
Number of subjects: 1350
Study 33952559 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable dose ibuprofen (10 mg/kg followed by two doses of 5 mg/kg at 24 hours intervals if treated within the first 7 days after birth; higher doses up to 20 mg/kg followed by two doses of 10 mg/kg at 24 hours intervals if treated after the postnatal age cut-off)
Number of subjects: 1350
Study 33952559 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (15 mg/kg every 6 hours for 3-7 days)
Number of subjects: 1350
Study 33952559 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous indomethacin (0.1-0.3 mg/kg intravenous every 12-24 hours for a total of three doses)
Number of subjects: 1350
Study 33952593 — intervention group
Group type: EXPERIMENTAL
Intervention: CLOSE-guided ablation
Number of subjects: 329
Study 33953626 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvenous phrenic nerve stimulation (TPNS) therapy
Number of subjects: 53
Study 33953800 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg daily
Number of subjects: 1087
Study 33953800 — intervention group
Group type: COMPARATOR
Intervention: No atorvastatin
Number of subjects: 1087
Study 33953800 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 1087
Study 33954223 — intervention group
Group type: EXPERIMENTAL
Intervention: Knot-tying suture-bridge repair
Number of subjects: 104